Three things the GLP-1 boom changed for everyone else
1. Consumer awareness of peptides went mainstream
Before semaglutide, “peptide” was a word most consumers didn't know. Skincare buyers had heard of copper peptides; biohackers had heard of BPC-157; almost nobody else had any meaningful peptide vocabulary.
After the GLP-1 wave hit mainstream media in 2024, that changed permanently. Consumers learned that peptides are a class of compounds, that they're used in clinical and wellness contexts, and that they're available outside traditional pharmacy channels. Search volume for non-GLP-1 peptides (BPC-157, GHK-Cu, TB-500) grew 200-400% in the same window.
For non-GLP-1 peptide brands, this meant a dramatically larger top-of-funnel audience — but also dramatically different consumer expectations. A buyer who first encountered “peptide” through a Hims GLP-1 ad arrives at a BPC-157 product page with assumptions about telehealth flows, prescriber consults, and FDA-approved mechanisms. Setting those expectations correctly is now part of the funnel.
2. Regulatory scrutiny tightened across the category
The FDA, state pharmacy boards, and state attorneys general all increased their attention on peptides as GLP-1 brought the category into political and media focus. This affected non-GLP-1 brands in several ways:
- State pharmacy boards issued warnings to compounding pharmacies about non-prescribed peptide sales, which constrained some research peptide suppliers.
- FDA warning letters to peptide brands tripled in 2024-2025 vs the prior period.
- Payment processors updated risk models to flag the broader peptide category, not just GLP-1 brands.
- Meta and other ad platforms updated restricted-product policies to capture more peptide variations.
Net effect: brands that operated quietly in 2023 found themselves under significantly more scrutiny in 2025-2026 even though they hadn't changed their products.
3. Investor + agency attention concentrated on GLP-1
VC capital, agency talent, and infrastructure investment all skewed heavily toward GLP-1 telehealth brands because of the larger TAM and clearer regulatory path. Non-GLP-1 peptide brands found:
- Fewer agencies willing to take them on — generalists moved into GLP-1, leaving research peptides underserved.
- Less venture capital — most peptide-focused VC activity in 2024-2025 funded GLP-1 telehealth, not research peptide brands.
- Less infrastructure investment — payment processors, email providers, and platforms that built for GLP-1 brands often still excluded research peptides specifically.
The opportunity for non-GLP-1 peptide brands
Despite the regulatory tightening and investor neglect, the non-GLP-1 segment of the peptide market in 2026 has structural advantages:
- Lower competition. The marketing attention is on GLP-1. Research peptide brands face less crowded auction prices on Meta and lower competition for SEO terms.
- Higher margins. No prescriber/pharmacy markup. A research peptide brand selling a $200 product keeps 60-70% margin where a GLP-1 telehealth brand keeps 30-40% after compounding pharmacy + prescriber costs.
- Educated buyers. The GLP-1 wave educated a generation of consumers about peptides generally. That awareness benefits every peptide brand, even ones with no GLP-1 product.
- Less platform risk concentrated in one compound.If FDA enforcement tightens specifically on compounded GLP-1 (a real risk for 2026-2027), research peptide brands selling other compounds aren't exposed.
What the next 12-24 months likely look like
Three predictions for late 2026 and 2027:
Compounded GLP-1 supply will normalize
Brand-name semaglutide (Ozempic, Wegovy) supply shortages were the regulatory justification for compounded GLP-1 sales. As supply normalizes, the FDA may restrict compounding pharmacies from producing semaglutide except for individualized patient needs. Many compounded GLP-1 telehealth brands will need to pivot.
Non-GLP-1 peptides will get more attention
As GLP-1 normalizes and the “novelty” wears off, agencies, investors, and infrastructure providers will start paying attention to the broader research peptide market. Expect more agencies specializing in this niche to emerge, and infrastructure built for it.
Compliance convergence accelerates
The gap between research-positioned and therapeutic-positioned peptide brands will continue to narrow as regulators apply consistent scrutiny. Brands operating cleanly in either lane will be more valuable; brands trying to straddle both will face increasing risk.
For non-GLP-1 peptide brands trying to navigate this environment, the marketing playbook is meaningfully different from what generalist agencies use. See our Meta ads service and research peptide advertising page for more.